Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study

BACKGROUND AND AIMS: Etrasimod is an oral, selective, sphingosine 1-phosphate receptor modulator. In a phase 2, randomised, double-blind, placebo-controlled trial in adults with moderately-to-severely active ulcerative colitis [OASIS], etrasimod 2 mg provided significant benefit versus placebo and w...

Descripción completa

Detalles Bibliográficos
Autores principales: Vermeire, Séverine, Chiorean, Michael, Panés, Julián, Peyrin-Biroulet, Laurent, Zhang, Jinkun, Sands, Bruce E, Lazin, Krisztina, Klassen, Preston, Naik, Snehal U, Cabell, Christopher H, Sandborn, William J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8218705/
https://www.ncbi.nlm.nih.gov/pubmed/33475734
http://dx.doi.org/10.1093/ecco-jcc/jjab016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8218705/
https://www.ncbi.nlm.nih.gov/pubmed/33475734
http://dx.doi.org/10.1093/ecco-jcc/jjab016

Ejemplares similares